Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Cube Infrastructure Fund II in connection with its investment in Bergkvarabuss
Mandate

Vinge advises Cube Infrastructure Fund II in connection with its investment in Bergkvarabuss

January 02, 2018 Employment and Benefits Automotive, Mobility and Electrification

Vinge has advised Cube Infrastructure Fund II in connection with its investment in Bergkvarabuss, which is a market leading company within the charter bus sector and one of the largest actors within procured line and school bus traffic.

Vinge’s team primarily consisted of Christina Kokko, Kristina Ekberg, Samra Baytar, Manne Bergström, Martin Cronsioe, Desirée Sjöblom, Ulrich Ziche, Hedvig Ekdahl, Josefine Lanker, Fredrika Hjelmberg, Viktor Wahlqvist, Lova Unge, Marion Kronberg, Jasmin Draszka-Ali and Xandra Ståhlberg.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026